Knebel Birgit, Müller-Wieland Dirk, Kotzka Jorg
German Diabetes-Center, Leibniz Center for Diabetes Research at Heinrich-Heine-University Düsseldorf, 40225 Düsseldorf, Germany.
Institute for Clinical Biochemistry and Pathobiochemistry, 40225 Düsseldorf, Germany.
Int J Mol Sci. 2020 Nov 20;21(22):8778. doi: 10.3390/ijms21228778.
Lipodystrophies are a heterogeneous group of physiological changes characterized by a selective loss of fatty tissue. Here, no fat cells are present, either through lack of differentiation, loss of function or premature apoptosis. As a consequence, lipids can only be stored ectopically in non-adipocytes with the major health consequences as fatty liver and insulin resistance. This is a crucial difference to being slim where the fat cells are present and store lipids if needed. A simple clinical classification of lipodystrophies is based on congenital vs. acquired and generalized vs. partial disturbance of fat distribution. Complications in patients with lipodystrophy depend on the clinical manifestations. For example, in diabetes mellitus microangiopathic complications such as nephropathy, retinopathy and neuropathy may develop. In addition, due to ectopic lipid accumulation in the liver, fatty liver hepatitis may also develop, possibly with cirrhosis. The consequences of extreme hypertriglyceridemia are typically acute pancreatitis or eruptive xanthomas. The combination of severe hyperglycemia with dyslipidemia and signs of insulin resistance can lead to premature atherosclerosis with its associated complications of coronary heart disease, peripheral vascular disease and cerebrovascular changes. Overall, lipodystrophy is rare with an estimated incidence for congenital (<1/1.000.000) and acquired (1-9/100.000) forms. Due to the rarity of the syndrome and the phenotypic range of metabolic complications, only studies with limited patient numbers can be considered. Experimental animal models are therefore useful to understand the molecular mechanisms in lipodystrophy and to identify possible therapeutic approaches.
脂肪营养不良是一组异质性的生理变化,其特征为脂肪组织的选择性丧失。在此情况下,由于缺乏分化、功能丧失或过早凋亡,不存在脂肪细胞。因此,脂质只能异位储存在非脂肪细胞中,从而产生如脂肪肝和胰岛素抵抗等主要健康后果。这与身材苗条有着关键区别,身材苗条者存在脂肪细胞,并在需要时储存脂质。脂肪营养不良的简单临床分类基于先天性与后天性以及脂肪分布的全身性与局部性紊乱。脂肪营养不良患者的并发症取决于临床表现。例如,糖尿病患者可能会出现微血管并发症,如肾病、视网膜病变和神经病变。此外,由于肝脏中异位脂质积聚,也可能发展为脂肪性肝炎,甚至可能发展为肝硬化。极高甘油三酯血症的后果通常是急性胰腺炎或发疹性黄瘤。严重高血糖与血脂异常及胰岛素抵抗迹象相结合,可导致过早发生动脉粥样硬化及其相关并发症,如冠心病、外周血管疾病和脑血管病变。总体而言,脂肪营养不良较为罕见,先天性(<1/1000000)和后天性(1 - 9/100000)形式的估计发病率分别如此。由于该综合征罕见且代谢并发症的表型范围广泛,只能考虑患者数量有限的研究。因此,实验动物模型有助于了解脂肪营养不良的分子机制并确定可能的治疗方法。